Berlin, Germany
Berlin, Germany

Time filter

Source Type

— The “Continuous Glucose Monitoring Systems Market - Medical Devices Pipeline Assessment, 2017” the report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Continuous Glucose Monitoring Systems pipeline products. Browse the 157 Tables and Figures, 70 Companies, Spread across 268 Pages Report Available at Scope of the Report: Extensive coverage of the Continuous Glucose Monitoring Systems under development The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities The report reviews the major players involved in the development of Continuous Glucose Monitoring Systems and list all their pipeline projects The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage The report provides key clinical trial data of ongoing trials specific to pipeline products Recent developments in the segment / industry Companies are mentioned: A. Menarini Diagnostics S.r.l., Abbott Diabetes Care, Inc., Advanced Biosensors-Ohio, Llc, Advanced Medical Electronics Corporation, Arkal Medical, Inc., Bio-Impedance General Ltd., Biorasis, Inc., Biovotion AG, CALISTO MEDICAL, INC. (Inactive), Cardiff University Company, City, University of London, Columbia University, ConvaTec Group Plc, Cyber Medical Ltd., Debiotech SA, DexCom Inc, DirectSens GmbH, Echo Therapeutics Inc, Ecole Polytechnique Federale de Lausanne, eLutions Integrated, EyeSense GmbH, Flowsion A/S, Gili Medical Ltd, Globe Medical Tech Inc, and Others. Place Order to This Report at Continuous Glucose Monitoring Systems Market- Recent Developments : Mar 30, 2017: ConvaTec Expands Unomedical Manufacturing Technology Partnership with Medtronic Diabetes to Meet Growing Demand Mar 29, 2017: ConvaTec Group: Directorate changes Mar 28, 2017: Novo Acquires 19.95% Stake in Convatec from Nordic Capital and Avista for USD1.22 Billion Mar 28, 2017: ConvaTec: Proposed Directorate Changes Mar 27, 2017: Integrity Applications Board Appoints John Graham CEO and Chairman, Angela Strand Vice Chairman Mar 24, 2017: Medicare Announces Criteria Covering Dexcom G5 Mobile CGM for All People with Diabetes on Intensive Insulin Therapy Mar 21, 2017: Medtronic Prices Public Offering of 1.7% Notes Due 2019 for USD1 Billion Mar 21, 2017: Medtronic Prices Public Offering of 3.35% Notes Due 2027 for USD850 Million Mar 21, 2017: Medtronic Prices Public Offering of 4.625% Notes Due 2045 for USD150 Million Mar 21, 2017: Tenax Therapeutics Announces Year-End 2016 Financial Results and Provides Corporate Update Mar 14, 2017: PositiveID’s E-N-G Mobile Systems’ 2017 Bookings Through February Total $1.7 Million, Up More than 200% from Prior Quarter Mar 13, 2017: DexCom Appoints Richard Collins to Board of Directors Mar 08, 2017: Tandem Diabetes Care Reports 2016 Financial Results Continuous Glucose Monitoring Systems Market- Recent Developments for 2017, January and February is also mentioned. List of Tables Table 1: Continuous Glucose Monitoring Systems - Pipeline Products by Stage of Development Table 2: Continuous Glucose Monitoring Systems - Pipeline Products by Segment Table 3: Continuous Glucose Monitoring Systems - Pipeline Products by Territory Table 4: Continuous Glucose Monitoring Systems - Pipeline Products by Regulatory Path Table 5: Continuous Glucose Monitoring Systems - Pipeline Products by Estimated Approval Date And more List of Figures Figure 1: Continuous Glucose Monitoring Systems - Pipeline Products by Stage of Development Figure 2: Continuous Glucose Monitoring Systems - Pipeline Products by Territory Figure 3: Continuous Glucose Monitoring Systems - Pipeline Products by Regulatory Path Figure 4: Continuous Glucose Monitoring Systems - Pipeline Products by Estimated Approval Date Figure 5: Continuous Glucose Monitoring Systems - Ongoing Clinical Trials Complete Table of Content is Available at Continuous Glucose Monitoring Systems - Medical Devices Pipeline Assessment, 2017. About Us: is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. For more information, please visit

News Article | November 16, 2016
Site: adds “Global Professional Diagnostics Market 2016-2020” new report to its research database. The report spread across 86 pages with table and figures in it. The research analysts forecast the global professional diagnostics market to grow at a CAGR of 6.76% during the period 2016-2020. About Professional Diagnostics The global professional diagnostics market is expected to grow at a high rate in the forecast period. Factors such as increasing aging population and rise in incidence and prevalence of chronic diseases and infections are driving the market. Cancer, tuberculosis, malaria, diabetes, and cardiovascular diseases are the main factors for the increasingly diagnosed population. In addition, increasing public awareness, rapid technological innovations, product approvals from regulatory authorities, and new product launches are expected to have a positive impact on the market over the next few years. Covered in this report The report covers the present scenario and the growth prospects of the global professional diagnostics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of in-vitro diagnostics (IVD) instruments. The market is divided into the following segments based on geography: Americas APAC EMEA Research report, Global Professional Diagnostics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Browse full table of contents and data tables at        Key vendors Abbott Diagnostics Danaher Roche Diagnostics Siemens Healthcare Thermo Fisher Scientific Other prominent vendors A&T Corporation Menarini Diagnostics Abaxis Abcam Accriva Diagnostics Acon Laboratories Affymetrix Ahram Biosystem ARKRAY AsuraGen Biocartis Bio-Rad Laboratories CellaVision Cepheid Chembio Diagnostic Systems Clarity Diagnostics Corgenix DiagCor Drucker Diagnostics EKF Molecular Diagnostics Erba Diagnostics Green Cross Medis Helena Laboratories Hologic HORIBA Instrumentation Laboratory i-Sens Landwind Medical Mindray Nihon Kohden Nipro Diagnostics Randox Laboratories Sekisui Medical Sienco Sinduri Biotec Snibe Diagnostics Stago Trivitron Healthcare Market driver Growing focus on diagnosing life-threatening conditions boosts POCT segment. For a full, detailed list, view our report Market challenge Industry consolidation posing threat to new entrants. For a full, detailed list, view our report Market trend Renting and leasing of professional diagnostics instruments. For a full, detailed list, view our report Key questions answered in this report What will the market size be in 2020 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors? To receive personalized assistance, write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150

Kubiak T.,University of Greifswald | Wittig A.,University of Greifswald | Koll C.,University of Greifswald | Mraz B.,Menarini Diagnostics | And 4 more authors.
Diabetes Technology and Therapeutics | Year: 2010

Background: QTc interval lengthening during hypoglycemia is discussed as a mechanism linked to sudden death in diabetes patients and the so-called "dead in bed syndrome." Previous research reported a high interindividual variability in the glucose-QTc association. The present study aimed at deriving parameters for direction and strength of the glucose-QTc association on the patient level using combined Holter electrocardiogram (ECG) and continuous glucose monitoring. Methods: Twenty type 1 diabetes patients were studied: mean (SD, range) age, 43.6 (10.8, 22-65) years; gender male (n [%]), 10 (50.0%); mean (SD) hemoglobin A1C, 8.5% (1.0%); and impaired hypoglycemia awareness (n [%]), six (30.0%). Continuous interstitial glucose monitoring and Holter ECG monitoring were performed for 48h. Hierarchical (mixed) regression modeling was used to account for the structure of the data. Results: Glucose levels during nighttime were negatively associated with QTc interval length if the data structure was accounted for (b [SE]=-0.76 [0.17], P=0.000). Exploratory regression analysis revealed hypoglycemia awareness as the only predictor of the individual strength of the glucose-QTc association, with the impaired awareness group showing less evidence for an association of low glucose with QTc lengthening. Conclusions: Mixed regression allows for deriving parameters for the glucose-QTc association on the patient level. Consistent with previous studies, we found a large interindividual variability in the glucose-QTc association. The finding on impaired hypoglycemia awareness patients has to be interpreted with caution but provides some support for the role of sympathetic activation for the QTc-glucose link. © Mary Ann Liebert, Inc.

Passamonti B.,U.O.C. di Citologia | Gustinucci D.,Menarini Diagnostics | Recchia P.,U.O.C. di Citologia | Bulletti S.,Menarini Diagnostics | And 8 more authors.
Pathologica | Year: 2010

The aim of this study was to assess the validity of protein p16 expression as an indicator of progression in lesions as ASC-US and L-SIL. For this purpose, we examined 246 cytological samples (91 ASC-US, 60 L-SIL, 36 ASC-H, 59 H-SIL) of which 151 were conventional Pap-tests (CC) and 95 in liquid based cytology (LBC) with colposcopic and histology follow-up. The results showed that in the positive p16 Pap-tests a 59% PPV vs CIN2+ in all cytologic diagnoses compared to 43% in cytologic reading alone. 96% of HG cytologic lesions were positive for pl6, and the data showed good correlation between positivity for pl6 in the cytologic preparations and the pres ence of CIN2+ lesions in the histologic test (chi-square for trend p< 0.0001). The sensitivity, specificity and NPV were 93%, 52% and 91%, respectively, in all cytologic diagnostic categories. P16 was positive in 46% of ASC-US and 53% of L-SIL. The PPV vs expressed CIN2+ was higher than that observed in cytologic reading (48% vs 26%, and 31% vs 20%, respectively). The sensitivity was 83%, the specificity 67% and 54%, respectively, and the VNP was 92% and 93%. It is possible to design algorithms for colposcopic follow-up that can reduce the need to obtain a follow-up. The future application of this test may allow the creation of a bio-molecular automated pap test.

Loading Menarini Diagnostics collaborators
Loading Menarini Diagnostics collaborators